News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

First SYGNIS Pharma AG QualiPhi® -Based Products Launched By QIAGEN Inc. (QGEN)



2/12/2014 1:36:29 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Madrid, Spain and Heidelberg, Germany, February 12th, 2014 –SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that its partner QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) the global leader in sample and assay technologies, launched the first two products of a series of kits based on SYGNIS’ proprietary amplification technology QualiPhi® now renamed SensiPhi®. The two kits, REPLI-g WTA Single Cell Kit and REPLIg Cell WGA & WTA Kit, are available now and will be commercialized globally through QIAGEN’s established distribution channels. The product launches result from a global exclusive license agreement with QIAGEN signed in 2012.

“We are at the beginning of a series of product launches that we believe will establish our polymerase as the potential future gold standard for isothermal amplification of DNA”, Pilar de la Huerta, CEO of SYGNIS stated. “With the launch of the first products based on our proprietary technology, SYGNIS continues to deliver on its objectives. It is a mark of our success as a company to have our product commercialized by the world leader QIAGEN.”

“We are very pleased with the launch of our new kits based on the polymerase provided by SYGNIS”, commented Achim Ribbe, Vice President Corporate Business Development Licensing at QIAGEN. “The REPLI-g WTA Single Cell and REPLI-g Cell WGA & WTA address key user challenges in NGS and other downstream applications, where DNA sequence analysis is limited by small amounts down to single cells of available sample material. To drive adoption of NGS in the clinical space, QIAGEN is building a broad portfolio of universal products including the REPLI-g Single Cell Kits which are compatible with any major NGS platform and which also support our own integrated sample-to-insight GeneReader workflow currently in development.”

SensiPhi® is the second generation of a DNA polymerase that was licensed from the Spanish National Research Council (CSIC) in 2010. Due to its unique properties, first studies suggest that it has the potential to improve the amplifications of whole genomes and large stretches of DNA. SYGNIS’ SensiPhi® is a high efficiency, high fidelity polymerase for DNA amplification which conveys the outstanding properties in terms of speed, accuracy and length of DNA fragments to be amplified. It differs from PCR since it provides generic amplification of the complete genome, whereas PCR is designed to detect predefined target sequences, and therefore only amplifies specific, mostly very short fragments of the DNA.

For further information please contact:
SYGNIS AG
Pilar de la Huerta
CEO/CFO
Tel: +34-918063089
Email: pdelahuerta@sygnis.es

About SYGNIS AG: www.sygnis.com
After the merger in 2012 between X-Pol Biotech, specializing in DNA amplification and sequencing, and SYGNIS AG, listed in the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), SYGNIS’ new mission is to develop and distribute technologies and products from X-Pol, which has a commercial product in the DNA amplification segment, SensiPhi® and is currently developing other products in the field of Next Generation Sequencing.

Disclaimer
This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES